KK 220
Alternative Names: Dianexin ophthalmic - Kowa; KK-220; Recombinant human annexin A5 ophthalmic - KowaLatest Information Update: 25 Jun 2010
Price :
$50 *
At a glance
- Originator Kowa
- Class Anti-inflammatories; Anti-ischaemics; Anticoagulants; Antithrombotics; Antivirals; Biological peptides; Calcium binding proteins; Cardiovascular therapies; Eye disorder therapies; Recombinant fusion proteins
- Mechanism of Action Urokinase-type plasminogen activator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 13 Jun 2008 Phase II development is ongoing
- 28 Feb 2006 This compound is still in active development
- 01 Jun 2005 Phase-II clinical trials in Eye disorders in Japan (Ophthalmic)